| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | ABT-263 | FIMM | pan-cancer | AAC | 0.029 | 0.8 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | -0.0082 | 0.8 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | lapatinib | FIMM | pan-cancer | AAC | -0.03 | 0.9 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.008 | 0.9 |